Recent Updates
Recently added Catalysts
ABT

New Research Finds Abbott's Optical Coherence Tomography Imaging Changed Treatment Decisions in 88% of Artery Blockages Abbott (NYSE: ABT) today announced new data from the company's LightLab Initiative that showed optical coherence tomography (OCT) imaging...

Key Takeaway: ABBOTT PARK, Ill., June 26, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced new data from the company's LightLab Initiative that showed optical coherence tomography (OCT) imaging significantly changes how physicians decide to treat a vessel compared to traditional angiog

Full Press Release Details

ABBOTT PARK, Ill., June 26, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced new data from the company's LightLab Initiative that showed optical coherence tomography (OCT) imaging significantly changes how physicians decide to treat a vessel compared to traditional angiography by providing physicians improved visualization within a patient's blood vessels. Data from the study revealed physicians altered their treatment strategy in 88% of coronary artery blockages based on new information provided by OCT.
Using laser technology, OCT captures high-resolution images inside a patient's arteries, displaying the type and severity of disease in the vessel, as well as enabling more accurate measurements to determine how the patient should be treated.
About the LightLab Initiative
Of the 2,203 procedures and 1,016 interventions that were assessed in the first phase of the LightLab Initiative, doctors used OCT before and after stenting in 652 lesions.
The level of detail and the volume of data collected in this real-world patient cohort demonstrates a clear and important impact of OCT on lesion assessment, procedural planning and stent optimization, with further analyses from subsequent phases of the program planned in coming months. The subsequent phases of the LightLab Initiative will focus on optimizing the prescribed treatment steps when using OCT to achieve greater efficiency (shorter timing) and safety (lower contrast and radiation exposure) gains, thereby identifying and removing barriers to OCT adoption.
About Optical Coherence Tomography
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal
1 Jones, Daniel A. et al "Angiography Alone Versus Angiography Plus Optical Coherence Tomography to Guide Percutaneous Coronary Intervention." JACC: Cardiovascular Interventions 11.14 (2018): 1313-1321. Web. 23 Aug. 2018 .

Related Links

21 %

Last updated: Jun 26, 2020